[6-K] Haleon plc Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reports the purchase of 1,500,000 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. The shares were bought on the London Stock Exchange/CBOE on 30 September 2025 at an average price of 331.3782 pence per share and will be held as treasury shares. After settlement the companys registered share capital is 8,952,353,648 ordinary shares, of which 44,400,783 are treasury shares, leaving 8,907,952,865 shares with voting rights. The announcement directs readers to a full breakdown of individual trades online.

Insights

Financial Analyst

TL;DR: A routine buyback tranche reducing outstanding voting shares modestly, using existing capital allocation priorities.

The purchase of 1.5 million shares at an average of 331.3782p is a clear execution of Haleons announced buyback programme and will reduce the number of shares outstanding for voting and EPS calculations by the treasury amount held. The trade size relative to total shares outstanding is small, so immediate per-share metric impacts will be modest. The company provides a trade breakdown link consistent with transparency requirements under the Market Abuse Regulation.

Corporate Governance Expert

TL;DR: Governance disclosure meets regulatory standards; treasury treatment and voting share update are clearly stated.

Haleon clearly states the intention to hold purchased shares as treasury shares and updates the count of voting shares, which helps shareholders determine disclosure obligations under FCA rules. The provision of an individual trade breakdown and website posting aligns with expected market abuse and disclosure practices. No governance concerns are apparent from this announcement alone.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	01 October 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

01 October 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,500,000 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	30 September 2025	30 September 2025	30 September 2025
Number of Shares purchased:	1,500,000	-	-
Highest price paid per Share (p):	333.3000	-	-
Lowest price paid per Share (p):	328.4000	-	-
Volume weighted average price paid per Share (p):	331.3782	-	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 44,400,783 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,907,952,865 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/5021B_1-2025-9-30.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: October 01, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary